Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
STAAR Surgical Co Market Cap
Based on ratings from 14 stock analysts, the STAAR Surgical Co stock price is expected to increase by 67.29% in 12 months. This is calculated by using the average 12-month stock price forecast for STAAR Surgical Co. The lowest target is $23 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
STAAR Surgical Co has a total of 14 Wall St Analyst ratings. There are 8 buy ratings, 5 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that STAAR Surgical Co will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of STAA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jon Young Canaccord Genuity | Hold | $28 | Maintains | Dec 9, 2024 |
| Jon Young Canaccord Genuity | Hold | $31 | Maintains | Nov 1, 2024 |
| David Saxon Needham | Hold | Reiterates | Oct 31, 2024 | |
| David Saxon Needham | Hold | Reiterates | Sep 19, 2024 | |
| Thomas Stephan Stifel | Buy | $44 | Maintains | Aug 26, 2024 |
| Jon Young Canaccord Genuity | Hold | $41 | Maintains | Aug 8, 2024 |
| David Saxon Needham | Hold | Reiterates | Aug 8, 2024 | |
| Ryan Zimmerman BTIG | Buy | $53 | Maintains | Jul 15, 2024 |
| David Saxon Needham | Hold | Reiterates | Jul 15, 2024 | |
| Patrick Wood Morgan Stanley | Underweight | $37 | Downgrade | Jul 15, 2024 |
| Ryan Zimmerman BTIG | Buy | $46 | Upgrade | Jun 11, 2024 |
| Matt O'Brien Piper Sandler | Neutral | $40 | Maintains | May 8, 2024 |
| Jon Young Canaccord Genuity | Hold | $43 | Maintains | May 8, 2024 |
| David Saxon Needham | Hold | Reiterates | May 8, 2024 | |
| Anthony Petrone Mizuho | Buy | $55 | Maintains | May 8, 2024 |
| Anthony Petrone Mizuho | Buy | $53 | Maintains | Apr 11, 2024 |
| Jon Young Canaccord Genuity | Hold | $46 | Maintains | Apr 8, 2024 |
| David Saxon Needham | Hold | Reiterates | Apr 4, 2024 | |
| Thomas Stephan Stifel | Buy | $50 | Maintains | Apr 1, 2024 |
| Thomas Stephan Stifel | Buy | $50 | Upgrade | Mar 11, 2024 |
When did it IPO
1992
Staff Count
1,056
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Thomas G. Frinzi
Market Cap
$1.29B
In 2023, STAA generated $322.4M in revenue, which was a increase of 13.37% from the previous year. This can be seen as a signal that STAA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - STAAR Surgical Company (NASDAQ: STAA) will participate in investor meetings and a fireside chat at the 4th Annual BTIG Ophthalmology Day on December 4, featuring CEO Thomas G. Frinzi.
Why It Matters - STAAR Surgical's participation in the BTIG Ophthalmology Day highlights its commitment to investor relations and could signal potential growth opportunities in the ophthalmic market, impacting stock performance.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - STAAR Surgical Company will participate in a webcast at the Stephens Annual Investment Conference in Nashville, TN, featuring management discussion on their EVO Implantable Collamer Lenses.
Why It Matters - The webcast at a notable investment conference offers insights into STAAR Surgical’s strategies and innovations, potentially influencing stock performance and investor sentiment.
Mon, 04 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Staar Surgical's reliance on international revenue is crucial for assessing its financial stability, growth potential, and stock price performance.
Why It Matters - Staar Surgical's reliance on international revenue affects its financial stability and growth potential, influencing stock price performance based on global market conditions and demand.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - STAAR Surgical (NASDAQ:STAA) will hold its Q3 2024 earnings conference call on October 30, 2024, at 4:30 PM ET, featuring key executives and analysts from major firms.
Why It Matters - The STAAR Surgical Q3 2024 earnings call offers insights into the company's financial performance and strategic direction, influencing stock valuation and investor sentiment.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - STAAR Surgical Company reported Q3 2024 net sales of $88.6 million, a 10% increase year-over-year. ICL sales also rose 10% to $89.1 million, with a gross margin of 77.3%.
Why It Matters - STAAR Surgical's 10% sales growth and strong gross margin indicate robust demand for its EVO ICL products, suggesting potential for continued revenue growth and profitability, influencing investor sentiment positively.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - STAAR Surgical revised its APAC sales growth forecast to 5% from 7%, with China expected to grow 2% (down from 10%) and other APAC countries 10-20% growth (previously flat).
Why It Matters - Revised APAC sales growth projections indicate weaker performance, particularly in China. This could signal declining demand and impact overall company revenue and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
